Friedrich Trendelenberg described ligation of the greater saphenous vein in 1890 as a treatment for varicose veins, and modifications of this procedure have been the mainstay of management for over a century. In recent decades, significant basic science breakthroughs have contributed enormously to clinical medicine in many fields, including arterial disease, cancer and microbiology. Although a large volume of basic science research is conducted in venous disease, these advances have not been mirrored in our specialty. Modern diagnostic tools are sophisticated and various modalities are available to ablate venous reflux, but the underlying principle governing the management of venous disease, i.e. the physical obliteration of the refluxing vein has not changed. With research funding and personnel becoming increasingly scarce, the value of basic science research in venous disease is unclear.
It should be acknowledged that advances in the understanding of venous disease pathophysiology have identified numerous potential therapeutic targets. Many important studies have shown increased leukocytes activation and recruitment in patients with venous hypertension, 1 confirming that venous hypertension causes local inflammation that may cause varicose vein wall remodelling and venous ulcer formation. Phlebotropic agents, such as micronized-purified flavonoid fraction, have anti-inflammatory and other effects on the venous remodelling process, and have been shown in prospective randomized studies to improve oedemarelated symptoms and venous ulcer healing. 1, 2 There is also increasing evidence that abnormalities in the balance of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) may contribute to the development of varicose veins and other complications of venous hypertension. 1 Therefore, agents such as the MMP inhibitor doxycycline may help to treat venous disease by modifying the MMP/TIMP balance. Moreover, important advances in the understanding of chronic wound pathophysiology have undoubtedly boosted the development of wound management products and biological dressings that remain the focus of ongoing studies. 2 There may be several reasons why few of the proposed therapeutic avenues have yielded significant breakthroughs in the prevention or treatment of venous disease. Perhaps, most importantly, there are still huge gaps in our understanding of basic inflammatory and collagen metabolism pathways, illustrated by the number of new MMPs and other factors that are discovered each year. Moreover, non-basic science-derived treatments, including surgery and compression, are extremely effective. 3 Much research energy (and money) has been focussed on refining and improving the delivery of these already efficacious interventions. Scientists are endlessly limited by the enormous heterogeneity in clinical presentation, severity and anatomical distribution in patients with venous disease. With the absence of a reliable animal model, studies are handicapped by the inevitable confounding factors, making it impossible to draw meaningful conclusions. Even if interesting correlations are identified, the causality of any relationships is difficult to prove. These hurdles have been overcome in other areas of research with adequate investment and public interest, but venous disease will never be able to compete with cancer or heart disease.
Despite these limitations, there are numerous outstanding questions that only basic science research can answer. Patients with identical patterns of venous reflux may have dramatically differing clinical presentations and the reasons why one leg may appear normal, whereas the other may have circumferential ulceration are unclear. The association between varicose veins and local inflammatory and protease pathways has been well established, but it is unknown whether these changes may have caused the formation of varicose veins, or may simply result from them. An exciting area of potential further research is the field of gene therapy and stem cell research. Potential genetic markers of venous insufficiency have already been identified 4 and although these fields are still in their infancy, their undoubted therapeutic potential in a variety of diseases is clear.
Venous disease may affect a quarter of the adult population and it is clear that basic science research has not yielded the significant breakthroughs that have been seen in other clinical areas. Nevertheless, important recent advances in gene mapping, chronic wound healing and varicose vein aetiology have been made and further development of these technologies must be continued. Clinicians and researchers must continue to support and encourage well-designed scientific research in venous disease so that this large cohort of patients is not denied potentially life-changing treatment in the future. 
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